{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Fluzone&page=13",
    "query": {
      "intervention": "Fluzone",
      "page": 13
    },
    "page_size": 10
  },
  "pagination": {
    "page": 13,
    "page_size": 10,
    "total_count": 1159,
    "total_pages": 116,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Fluzone&page=14&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Fluzone&page=12&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-18T15:54:47.049Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03438487",
      "title": "Flucelvax (TIVc or QIVc) Pregnancy Registry",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Influenza, Human",
        "Pregnancy",
        "Birth Defect"
      ],
      "interventions": [
        {
          "name": "Flucelvax Trivalent Influenza Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Flucelvax Quadrivalent Influenza Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Seqirus",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "Female only"
      },
      "enrollment_count": 692,
      "start_date": "2017-09-01",
      "completion_date": "2020-12-31",
      "has_results": false,
      "last_update_posted_date": "2022-11-04",
      "last_synced_at": "2026-10-18T15:54:47.049Z",
      "location_count": 1,
      "location_summary": "Wilmington, North Carolina",
      "locations": [
        {
          "city": "Wilmington",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03438487"
    },
    {
      "nct_id": "NCT05655546",
      "title": "ImmunoCARE: Rapid, Accurate COVID Testing to Reduce Hospitalization of Immunocompromised Individuals",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Immunodeficiency",
        "Immunosuppression",
        "HIV Infections",
        "Graft Versus Host Disease",
        "Leukemia",
        "Lymphoma",
        "Cancer",
        "Multiple Myeloma",
        "Transplant",
        "Age-Related Immunodeficiency"
      ],
      "interventions": [
        {
          "name": "Access to Cue Health COVID-19 Remote testing and treatment for COVID-19",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Scripps Translational Science Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 2117,
      "start_date": "2022-12-22",
      "completion_date": "2024-06-20",
      "has_results": true,
      "last_update_posted_date": "2025-08-08",
      "last_synced_at": "2026-10-18T15:54:47.049Z",
      "location_count": 1,
      "location_summary": "La Jolla, California",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05655546"
    },
    {
      "nct_id": "NCT03698279",
      "title": "Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 30 μg (split-virion, inactivated)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 45 μg, (split-virion, inactivated)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 60 µg (split-virion, inactivated)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Fluarix Quadrivalent Influenza vaccine (Unadjuvanted QIV-SD) (Inactivated)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "FLUAD Pediatric (adjuvanted TIV) (Surface Antigen, Inactivated)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sanofi Pasteur, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "6 Months to 17 Years"
      },
      "enrollment_count": 665,
      "start_date": "2018-10-09",
      "completion_date": "2019-10-16",
      "has_results": true,
      "last_update_posted_date": "2022-04-04",
      "last_synced_at": "2026-10-18T15:54:47.049Z",
      "location_count": 13,
      "location_summary": "San Diego, California • Miami, Florida • Atlanta, Georgia + 8 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "El Dorado",
          "state": "Kansas"
        },
        {
          "city": "Newton",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03698279"
    },
    {
      "nct_id": "NCT01990846",
      "title": "Safety, Tolerability, and PK of Escalating Doses of Flufirvitide-3 Dry Powder for Inhalation in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "Flufirvitide 3",
          "type": "DRUG"
        },
        {
          "name": "Placebo for Flufirvitide-3",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Autoimmune Technologies, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 68,
      "start_date": "2014-03",
      "completion_date": "2015-02",
      "has_results": false,
      "last_update_posted_date": "2015-03-11",
      "last_synced_at": "2026-10-18T15:54:47.049Z",
      "location_count": 1,
      "location_summary": "Spartanburg, South Carolina",
      "locations": [
        {
          "city": "Spartanburg",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01990846"
    },
    {
      "nct_id": "NCT01776541",
      "title": "Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pandemic H5N1 Influenza"
      ],
      "interventions": [
        {
          "name": "Adjuvanted H5N1 pandemic influenza vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Novartis Vaccines",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 979,
      "start_date": "2013-01",
      "completion_date": "2014-05",
      "has_results": true,
      "last_update_posted_date": "2015-02-03",
      "last_synced_at": "2026-10-18T15:54:47.049Z",
      "location_count": 4,
      "location_summary": "Miami, Florida • St Louis, Missouri • Austin, Texas",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01776541"
    },
    {
      "nct_id": "NCT04597554",
      "title": "Cranberry Supplementation, Viral Defense, Antibody Response to the Flu Shot",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Nutrition Immunology"
      ],
      "interventions": [
        {
          "name": "Cranberry",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Placebo",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Appalachian State University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "40 Years to 80 Years"
      },
      "enrollment_count": 84,
      "start_date": "2020-09-21",
      "completion_date": "2021-12-31",
      "has_results": false,
      "last_update_posted_date": "2022-02-21",
      "last_synced_at": "2026-10-18T15:54:47.049Z",
      "location_count": 1,
      "location_summary": "Kannapolis, North Carolina",
      "locations": [
        {
          "city": "Kannapolis",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04597554"
    },
    {
      "nct_id": "NCT00551031",
      "title": "Study of Inactivated, Split-Virion Influenza Vaccine and Standard Fluzone® Vaccine in Adult and Elderly Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Influenza",
        "Myxovirus Infection"
      ],
      "interventions": [
        {
          "name": "Split, Inactivated, Trivalent Influenza Vaccine (Intradermal Formulation 1)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Split, Inactivated, Trivalent Influenza Vaccine (Intradermal Formulation 2)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Split, Inactivated, Trivalent Influenza Vaccine (Standard dose)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Split, Inactivated, Trivalent Influenza Vaccine (High-dose)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2098,
      "start_date": "2007-10",
      "completion_date": "2008-11",
      "has_results": true,
      "last_update_posted_date": "2016-05-16",
      "last_synced_at": "2026-10-18T15:54:47.049Z",
      "location_count": 29,
      "location_summary": "Alabaster, Alabama • Mobile, Alabama • Chandler, Arizona + 26 more",
      "locations": [
        {
          "city": "Alabaster",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00551031"
    },
    {
      "nct_id": "NCT01959945",
      "title": "Safety, Reactogenicity and Immunogenicity of Flublok Quadrivalent (Recombinant Influenza Vaccine,Seasonal Formulation)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "Flublok® Quadrivalent Influenza Virus Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Fluarix Quadrivalent® Influenza Virus Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Protein Sciences Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "6 Years to 17 Years"
      },
      "enrollment_count": 219,
      "start_date": "2013-11",
      "completion_date": "2014-10",
      "has_results": true,
      "last_update_posted_date": "2016-09-23",
      "last_synced_at": "2026-10-18T15:54:47.049Z",
      "location_count": 1,
      "location_summary": "Auburn, Maine",
      "locations": [
        {
          "city": "Auburn",
          "state": "Maine"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01959945"
    },
    {
      "nct_id": "NCT00133471",
      "title": "Inactivated Influenza A/H9N2 Vaccine With and Without MF59 Adjuvant in Ambulatory Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "Influenza A/H9N2 vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MF59 adjuvant",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "34 Years",
        "sex": "ALL",
        "summary": "18 Years to 34 Years"
      },
      "enrollment_count": 96,
      "start_date": "2005-03",
      "completion_date": "2005-12",
      "has_results": false,
      "last_update_posted_date": "2010-08-27",
      "last_synced_at": "2026-10-18T15:54:47.049Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00133471"
    },
    {
      "nct_id": "NCT00953524",
      "title": "A Study of Different Formulations of an A/H1N1 Pandemic Vaccine in Healthy Adults and the Elderly",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Influenza",
        "Swine-origin A/H1N1 Influenza"
      ],
      "interventions": [
        {
          "name": "Monovalent Subvirion A/H1N1 Influenza vaccine (7.5 µg of HA)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Monovalent Subvirion A/H1N1 Influenza vaccine (15 µg of HA)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Monovalent Subvirion A/H1N1 Influenza vaccine (30 µg of HA)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Normal saline solution (placebo)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sanofi Pasteur, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 849,
      "start_date": "2009-08",
      "completion_date": "2010-12",
      "has_results": true,
      "last_update_posted_date": "2014-03-10",
      "last_synced_at": "2026-10-18T15:54:47.049Z",
      "location_count": 15,
      "location_summary": "Hoover, Alabama • Chandler, Arizona • Phoenix, Arizona + 12 more",
      "locations": [
        {
          "city": "Hoover",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "South Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00953524"
    }
  ]
}